Search

DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead

DBV REJOINS PEANUT ALLERGY TREATMENT RACE, BUT AIMMUNE TAKES THE LEAD

DBV Technologies is jumping back into the race to bring an FDA-approved peanut allergy treatment to the market, but it might not be...

GREY WOLF BAGS CASH TO ADVANCE SMALL MOLECULE I/O PROGRAM

Grey Wolf Therapeutics has raised £10 million to advance small molecules that help the immune system recognize tumors. The series A,...

 
 
 

CUREVAC WALKS AWAY FROM ARCTURUS' UREA CYCLE DISORDER DRUG, BUT PARTNERSHIP REMAINS INTACT

Arcturus Therapeutics had a melodramatic 2018 - the San Diego biotech's CEO Joseph Payne was asked to leave for putting his interests...

CANAAN LEAPS INTO UK BIOTECH BY CO-LEADING $14M SERIES A FOR IMMUNO-ONCOLOGY UPSTART GREY WOLF

Checkpoint inhibitors have done wonders for immuno-oncology, but the potent class of drugs doesn't work across all cancers. To remedy...

 
 
 
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More

BIO ROUNDUP: NEW CRISPR FEUD, A NY SPLASH, PHARMA VS. CONGRESS & MORE

If you're into congressional spectacles, stay tuned later this month. A group of top biopharma executives-the full roster isn't known...

Harpoon's IPO Spears $76M as Prostate Cancer Drug Continues Testing

HARPOON'S IPO SPEARS $76M AS PROSTATE CANCER DRUG CONTINUES TESTING

Cancer immunotherapy developer Harpoon Therapeutics is the latest biotech to enter the public markets, raising approximately $76 million...

 
 
 
First US attempt to cure a rare disease with genome editing fails miserably 

FIRST US ATTEMPT TO CURE A RARE DISEASE WITH GENOME EDITING FAILS MISERABLY 

Sangamo Therapeutics tried to cure two forms of a rare genetic disease using 'zinc finger' gene editing. They successfully changed...

Seres Lays Off 30% of Staff, CSO Leaves After Pipeline Review

SERES LAYS OFF 30% OF STAFF, CSO LEAVES AFTER PIPELINE REVIEW

Seres Therapeutics was one of the first microbiome companies to form back in 2010. And the Flagship Pioneering company was the first...

 
 
 
With Its First Human Data, Solid Slips in Duchenne Gene Therapy Race

WITH ITS FIRST HUMAN DATA, SOLID SLIPS IN DUCHENNE GENE THERAPY RACE

The race to treat Duchenne muscular dystrophy with gene therapy, a one-time, potentially long-lasting treatment, is being closely watched....

Research proves the healing potential of monk fruit on cancer patients

RESEARCH PROVES THE HEALING POTENTIAL OF MONK FRUIT ON CANCER PATIENTS

Monk fruit is one of the stalwarts of traditional Chinese medicine that found new uses in modern times. Many studies are now confirming...

 
 
 

LIGAND ANNOUNCES INVESTMENT IN DIANOMI THERAPEUTICS

SAN DIEGO--Ligand Pharmaceuticals Incorporated announces closing an investment in Dianomi Therapeutics, Inc., a biopharmaceutical company...

ARGENX AND HALOZYME ENTER GLOBAL COLLABORATION AND LICENSE AGREEMENT FOR ENHANZE® TECHNOLOGY

Argenx gains access to ENHANZE® subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic...

 
 
 
Dewpoint Debuts with $60M to Target Protein Droplets Linked to Disease

DEWPOINT DEBUTS WITH $60M TO TARGET PROTEIN DROPLETS LINKED TO DISEASE

An exciting new area of cell biology research that has emerged in only the last decade has already spawned a startup, which launches...

Scaling up the Manufacturing Process of Adoptive T Cell Immunotherapy

SCALING UP THE MANUFACTURING PROCESS OF ADOPTIVE T CELL IMMUNOTHERAPY

Standardizing the manufacturing process is of the ultimate importance for scaling up Adoptive Cell Therapy , where closed system, automation,...

 
 
 

LECITHIN NANO-LIPOSOMAL PARTICLE AS A CRISPR/CAS9 COMPLEX DELIVERY SYSTEM FOR TREATING TYPE 2 DIABETES

Protein-based Cas9 in vivo gene editing therapeutics have practical limitations owing to their instability and low efficacy. To overcome...

 
 
 
Former Insys execs in alleged opioid conspiracy start criminal trial in Boston

FORMER INSYS EXECS IN ALLEGED OPIOID CONSPIRACY START CRIMINAL TRIAL IN BOSTON

The trial - of Insys founder John Kapoor and four other defendants - had been scheduled to start Monday morning. Two other executives...

Former Zavante Executive Tapped as Abide Therapeutics President

FORMER ZAVANTE EXECUTIVE TAPPED AS ABIDE THERAPEUTICS PRESIDENT

Abide Therapeutics, which is developing medicines to treat neurological diseases, has appointed Kevin Finney as its president and chief...

 
 
 

MIRATI THERAPEUTICS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

SAN DIEGO, Jan. 22, 2019 /PRNewswire/ - Mirati Therapeutics, Inc. today announced the closing of its previously announced underwritten...

WREN RAISES £18M TO DRUG PROTEIN-MISFOLDING DISEASES

Wren Therapeutics has raised £18 million. The British biotech will use the series A round to advance its research into drugs to treat...